What are the recommended pneumococcal vaccination guidelines for adults (including those ≥65 years, high‑risk 19‑64‑year‑olds, and immunocompromised patients) and children?

Pneumococcal Vaccination Guidelines for Adults and Children

All adults aged ≥50 years should receive a single dose of pneumococcal conjugate vaccine (PCV), with options including PCV20, PCV21, or PCV15 (followed by PPSV23), and all adults aged ≥65 years must receive PPSV23 regardless of prior vaccination history. 1

Adults Aged ≥65 Years (Immunocompetent)

For healthy adults ≥65 years without prior pneumococcal vaccination:

• Administer one dose of PCV20, PCV21, or PCV15 2
• If PCV15 is chosen, follow with PPSV23 ≥1 year later 2
• All adults ≥65 years must receive at least one dose of PPSV23, administered ≥1 year after any PCV (or ≥5 years after any prior PPSV23 given before age 65) 2

Important change from 2019: PCV13 is no longer routinely recommended for all adults ≥65 years; instead, it is based on shared clinical decision-making for those without immunocompromising conditions, CSF leak, or cochlear implant 2. This change occurred because indirect protection from pediatric PCV13 vaccination reduced disease burden to historically low levels, making universal adult PCV13 vaccination cost-ineffective ($200,000-$560,000 per QALY versus $65,000 in 2014) 2.

For adults ≥65 years who previously received PCV13 and PPSV23:

• Shared clinical decision-making regarding additional PCV20 or PCV21 dose ≥5 years after last pneumococcal vaccine 2
• Consider individual exposure risk and underlying medical conditions when deciding 2

Adults Aged 19-64 Years with High-Risk Conditions

Immunocompromised patients (including HIV, malignancy, transplant, asplenia, chronic renal failure, immunosuppressive therapy):

• Mandatory PCV vaccination: Administer PCV20, PCV21, or PCV15 2
• If PCV15 used, follow with PPSV23 ≥8 weeks later (shorter interval than immunocompetent) 2
• Administer second PPSV23 dose ≥5 years after first PPSV23 2
• Critical timing: The 8-week interval (versus 1 year for immunocompetent) reflects higher disease risk and need for rapid protection 2

Patients with cochlear implants or CSF leaks:

• Same regimen as immunocompromised: PCV followed by PPSV23 ≥8 weeks later 2
• These anatomic defects create direct pathways for pneumococcal invasion, warranting aggressive vaccination 2

Immunocompetent adults 19-64 years with chronic conditions (diabetes, heart disease, lung disease, liver disease, alcoholism, smoking):

• Administer one dose of PPSV23 2
• No routine PCV recommendation for this group unless they reach age ≥50 years 1
• If PPSV23 given before age 65, administer additional PPSV23 dose at age ≥65 years (≥5 years after prior PPSV23) 2

Adults Aged 50-64 Years (New 2024 Recommendation)

All PCV-naïve adults aged ≥50 years should receive a single dose of PCV (PCV20, PCV21, or PCV15+PPSV23), regardless of risk factors. 1

• This represents an expansion from the previous age ≥65 threshold 1
• Provides earlier protection during years when pneumococcal disease incidence begins rising 1

Vaccine Sequencing and Timing

When both PCV and PPSV23 are indicated:

• Always administer PCV first, then PPSV23 2
• Never coadminister PCV and PPSV23 on the same day 2

Intervals between vaccines:

• Immunocompetent: ≥1 year between PCV and PPSV23 2
• Immunocompromised/CSF leak/cochlear implant: ≥8 weeks between PCV and PPSV23 2
• Between PPSV23 doses: ≥5 years 2

If PPSV23 was given first (out of sequence):

• Wait ≥1 year, then administer PCV 2
• This corrects the suboptimal sequence while maintaining safety 2

Special Populations

Adults with prior PCV13 only:

• May receive PCV20, PCV21, or PPSV23 ≥1 year after PCV13 2
• If immunocompromised, PPSV23 can be given ≥8 weeks after PCV13 2

Adults who received PCV7 (older 7-valent vaccine):

• Treat as unvaccinated; administer current PCV recommendations 2

Serotype Coverage Considerations

In populations where ≥30% of pneumococcal disease is serotype 4:

• Prefer PCV20 or PCV15+PPSV23 over PCV21 (which lacks serotype 4) 2
• This applies to certain geographic regions or institutional outbreaks 2

Common Pitfalls to Avoid

Critical errors:

• Forgetting PPSV23 in adults ≥65 years who received only PCV—PPSV23 covers 11 additional serotypes accounting for 32-37% of invasive disease in this age group 2
• Using 1-year interval for immunocompromised patients instead of 8 weeks—delays protection in highest-risk patients 2
• Administering more than one PPSV23 dose after age 65—no additional doses recommended after the dose given at ≥65 years 2
• Failing to vaccinate adults 50-64 years under new 2024 guidelines 1

Documentation issues:

• Unknown vaccination history: Treat as unvaccinated rather than assuming prior vaccination 2
• PCV7 history: Does not count toward current recommendations 2

Coadministration with Other Vaccines

Pneumococcal vaccines may be administered simultaneously with other age-appropriate vaccines (including COVID-19, influenza, RSV) at different injection sites. 2